DarwinHealth is an American biomedical company that uses algorithms and mathematical models in combination with wet lab experiments to develop cancer medicine.[1][2] It is headquartered in New York, U.S.[3]
| Company type | Private |
|---|---|
| Founded | 2015 |
| Founders | Andrea Califano Gideon Bosker |
| Headquarters | New York , United States |
| Website | darwinhealth |
History
editDarwinHealth was founded in 2015 by Andrea Califano and Gideon Bosker.[4][5] Their collaboration began after a meeting in the British Virgin Islands in 2013.[6] The company's approach is to utilize algorithms developed in the Califano Lab at Columbia University to help physicians identify transcription factors in tumors and to predict potential drug targets and treatments.[6][7]
In 2018, Daiichi Sankyo and DarwinHealth entered into a research collaboration centered on identifying novel cancer targets.[8]
In 2019, DarwinHealth and Celgene entered into a scientific collaboration to prioritize the oncology-relevant bioactivity of oncology compounds using its algorithmic framework with the goal of identifying their mechanism of action (MOA) against Master Regulator (MR) proteins.[9]
In 2021, Bristol Myers Squibb collaborated with DarwinHealth to explore compounds that might target master regulators within their compound library.[6][10] In October 2021, DarwinHealth and Prelude Therapeutics collaborated to identify biomarkers for oncology drug trials.[11]
Research
editIn 2016, Andrea Califano of DarwinHealth, together with his colleague Mariano Alvarez, introduced the concept of "oncotecture" in a paper published in Nature Reviews Cancer.[12] They elucidated "master regulator" proteins that consistently impact tumor development across various patients.[12] By analyzing gene-expression profiles from 20,000 tumor samples, Califano identified approximately 300 potential master regulators across 36 tumor types. These proteins primarily influence transcription.[12]
In 2019, in a New England Journal of Medicine article titled, "Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma", analyzed patients from the STORM clinical trial for multiple myeloma.[13] In this trial, patients were treated with the XPO1 inhibitor selinexor. DarwinHealth scientists identified a Linear Discriminant Analysis (LDA) classifier using VIPER-assessed activity of only four proteins (IRF3, ARL2BP, ZBTB17, and ATRX).[13] The DarwinOncoMarker achieved a predictability measure (AUC = 0.862) in distinguishing responders from non-responders, a finding also confirmed in an independent cohort.[13]
In 2022, researchers from DarwinHealth published a paper in Current Protocols outlining the methodologies of the DarwinOncoDiscovery cancer drug discovery platform.[7] The protocol identifies tumor checkpoint MRs from patient samples and selects relevant in vitro and in vivo models to discern tissue-specific drug MOAs.[7] This method refines preclinical drug validations, enhancing the selection process for clinical trial participants.[7]
Products and services
editReferences
edit- ^ "DarwinHealth, Inc". Nature Index. October 31, 2023.
- ^ "DarwinHealth Applies Systems Bio Workflow to Improve Clinical Trial Patient Matching | GenomeWeb".
- ^ Califano, Andrea; Bosker, Gideon (23 September 2016). "Can Math Crack Cancer's Code?". Wall Street Journal.
- ^ Echeverria, Gloria V.; Ge, Zhongqi; Seth, Sahil; Zhang, Xiaomei; Jeter-Jones, Sabrina; Zhou, Xinhui; Cai, Shirong; Tu, Yizheng; McCoy, Aaron; Peoples, Michael; Sun, Yuting; Qiu, Huan; Chang, Qing; Bristow, Christopher; Carugo, Alessandro; Shao, Jiansu; Ma, Xiaoyan; Harris, Angela; Mundi, Prabhjot; Lau, Rosanna; Ramamoorthy, Vandhana; Wu, Yun; Alvarez, Mariano J.; Califano, Andrea; Moulder, Stacy L.; Symmans, William F.; Marszalek, Joseph R.; Heffernan, Timothy P.; Chang, Jeffrey T.; Piwnica-Worms, Helen (2019). "Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state". Science Translational Medicine. 11 (488). doi:10.1126/scitranslmed.aav0936. PMC 6541393. PMID 30996079.
- ^ "About – DarwinHealth".
- ^ a b c d e https://www.science.org/content/article/computer-algorithms-find-tumors-molecular-weak-spots
- ^ a b c d Laise, Pasquale; Bosker, Gideon; Califano, Andrea; Alvarez, Mariano J. (September 13, 2022). "A Patient‐to‐Model‐to‐Patient (PMP) Cancer Drug Discovery Protocol for Identifying and Validating Therapeutic Agents Targeting Tumor Regulatory Architecture". Current Protocols. 2 (9): e544. doi:10.1002/cpz1.544. PMID 36083100. S2CID 252160965 – via CrossRef.
- ^ "Daiichi Sankyo And Darwinhealth Enter Exclusive Research Collaboration For Novel Cancer Target Initiative". Reuters. April 4, 2018.
- ^ https://www.drugdiscoverynews.com/a-cancer-research-collaboration-13596
- ^ "DarwinHealth, Bristol Myers Squibb sign research collaboration to identify novel cancer targets across a range of tumor subtypes". pharmabiz.com.
- ^ "DarwinHealth, Prelude Therapeutics Partner to ID Biomarkers for Oncology Drug Trials". Precision Medicine Online.
- ^ a b c "A new type of molecular medicine may be needed to halt cancers". The Economist.
- ^ a b c Chari, Ajai; Vogl, Dan T.; Gavriatopoulou, Maria; Nooka, Ajay K.; Yee, Andrew J.; Huff, Carol A.; Moreau, Philippe; Dingli, David; Cole, Craig; Lonial, Sagar; Dimopoulos, Meletios; Stewart, A. Keith; Richter, Joshua; Vij, Ravi; Tuchman, Sascha; Raab, Marc S.; Weisel, Katja C.; Delforge, Michel; Cornell, Robert F.; Kaminetzky, David; Hoffman, James E.; Costa, Luciano J.; Parker, Terri L.; Levy, Moshe; Schreder, Martin; Meuleman, Nathalie; Frenzel, Laurent; Mohty, Mohamad; Choquet, Sylvain; Schiller, Gary; Comenzo, Raymond L.; Engelhardt, Monika; Illmer, Thomas; Vlummens, Philip; Doyen, Chantal; Facon, Thierry; Karlin, Lionel; Perrot, Aurore; Podar, Klaus; Kauffman, Michael G.; Shacham, Sharon; Li, Lingling; Tang, Shijie; Picklesimer, Carla; Saint-Martin, Jean-Richard; Crochiere, Marsha; Chang, Hua; Parekh, Samir; Landesman, Yosef; Shah, Jatin; Richardson, Paul G.; Jagannath, Sundar (August 22, 2019). "Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma". New England Journal of Medicine. 381 (8): 727–738. doi:10.1056/NEJMoa1903455. PMID 31433920. S2CID 201275272 – via CrossRef.
- ^ a b "Darwin OncoTarget™/OncoTreat™". Pathology. February 8, 2018.